Israeli biopharma BioLineRx's Q3 loss narrows as costs drop

Reuters11-24
Israeli biopharma BioLineRx's Q3 loss narrows as costs drop

Overview

  • BioLineRx reports Q3 net loss of $1 mln, narrower than $5.8 mln loss in year-ago quarter

  • Company says joint venture plan with Hemispherian to advance GLIX1 cancer therapeutic was a Q3 highlight

  • BioLineRx maintains cash runway guidance into first half of 2027

Outlook

  • BioLineRx plans to start Phase 1/2a trial for GLIX1 in Q1 2026

  • Company maintains cash runway guidance into first half of 2027

  • Patent for GLIX1 extends protection until 2040

Result Drivers

  • RESEARCH COSTS DROP - R&D expenses decreased 33% mainly on licensing of U.S. motixafortide right to Ayrmid and lower payroll costs after headcount reduction

  • LOWER EXPENSES - Sales and marketing costs fell mainly due to shutdown of U.S. commercial operations in Q4 2024 after Ayrmid licensing deal and a drop in G&A costs

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Income

-$1 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for BioLine RX Ltd is $26.00, about 87.5% above its November 21 closing price of $3.25

Press Release: ID:nPnbvftJMa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment